T P Laughren

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective
    T P Laughren
    Psychiatric Drug Products Group, Division of Neuropharmacological Drug Products HFD 120, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, USA
    Eur Psychiatry 16:418-23. 2001
  2. ncbi Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim
    Thomas Laughren
    Food and Drug Administration, DNDP, HFD 120, 5600 Fishers Lane, Rockville, MD 20853, USA
    Schizophr Bull 32:220-2. 2006
  3. ncbi Suicidality in pediatric patients treated with antidepressant drugs
    Tarek A Hammad
    Division of Neuropharmacological Drug Products, HFD 120, 5600 Fishers Lane, Rockville, MD 20857, USA
    Arch Gen Psychiatry 63:332-9. 2006
  4. ncbi A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 31:5-19. 2005
  5. ncbi Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop
    Alan S Bellack
    University of Maryland School of Medicine, 737 West Lombard Street, Suite 551, Baltimore, MD 21201, USA
    Schizophr Bull 33:805-22. 2007
  6. ncbi Wayne Fenton: impact on food and drug administration
    Thomas Laughren
    Schizophr Bull 33:1153. 2007
  7. ncbi Developing strategies for psychopharmacological studies in preschool children
    Laurence L Greenhill
    New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    J Am Acad Child Adolesc Psychiatry 42:406-14. 2003
  8. ncbi Conventional vs. atypical antipsychotic medications
    Marc Stone
    N Engl J Med 354:972-4; author reply 972-4. 2006

Detail Information

Publications8

  1. ncbi The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective
    T P Laughren
    Psychiatric Drug Products Group, Division of Neuropharmacological Drug Products HFD 120, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, USA
    Eur Psychiatry 16:418-23. 2001
    ..Preliminary data on suicides in placebo-controlled depression and schizophrenia trials will be presented to argue for the ethical acceptability of the conduct of placebo-controlled trials in these two conditions...
  2. ncbi Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim
    Thomas Laughren
    Food and Drug Administration, DNDP, HFD 120, 5600 Fishers Lane, Rockville, MD 20853, USA
    Schizophr Bull 32:220-2. 2006
    ....
  3. ncbi Suicidality in pediatric patients treated with antidepressant drugs
    Tarek A Hammad
    Division of Neuropharmacological Drug Products, HFD 120, 5600 Fishers Lane, Rockville, MD 20857, USA
    Arch Gen Psychiatry 63:332-9. 2006
    ..There has been concern that widely used antidepressant agents might be associated with an increased risk of suicidal ideation and behavior (suicidality) in pediatric patients...
  4. ncbi A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
    Robert W Buchanan
    Maryland Psychiatric Research Center, P O Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 31:5-19. 2005
    ....
  5. ncbi Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop
    Alan S Bellack
    University of Maryland School of Medicine, 737 West Lombard Street, Suite 551, Baltimore, MD 21201, USA
    Schizophr Bull 33:805-22. 2007
    ..quot; This criterion is problematic because different observers and constituencies often have different opinions about what types of change are clinically important and how much change is significant...
  6. ncbi Wayne Fenton: impact on food and drug administration
    Thomas Laughren
    Schizophr Bull 33:1153. 2007
  7. ncbi Developing strategies for psychopharmacological studies in preschool children
    Laurence L Greenhill
    New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    J Am Acad Child Adolesc Psychiatry 42:406-14. 2003
    ..To identify the obstacles and special challenges-ethical, practical, scientific, and regulatory-faced by investigators who attempt to conduct psychopharmacological studies in preschoolers...
  8. ncbi Conventional vs. atypical antipsychotic medications
    Marc Stone
    N Engl J Med 354:972-4; author reply 972-4. 2006